Honored as "Excellent Enterprise in Artificial Intelligence"
Recently, the results of the 2025 China Outstanding Sci-Tech Innovation Enterprises selection, jointly launched by Cls.cn and Sci-Tech Innovation Board Daily, were officially unveiled.
Leveraging its groundbreaking innovations and core capabilities in the biomanufacturing sector empowered by the self-developed AI protein design large model, Shanghai Matwings Technology Co., Ltd. (hereinafter referred to as “Matwings”) stood out and was awarded the title of Excellent Enterprise in Artificial Intelligence.
The selection of China Outstanding Sci-Tech Innovation Enterprises is rooted in in-depth industry insights. It aims to benchmark leading enterprises representing China’s new quality productivity from multiple dimensions, including technological innovation, commercial potential and capital attention. Matwings’s standout performance in the Excellent Enterprise in Artificial Intelligence track not only validates its solid strength in AI technology, but also reflects high market recognition of the innovative AI + Biomanufacturing model.
Currently, generative AI has become a core engine driving advances in life sciences, and AI protein design serves as a key driver for the upgrading of the biomanufacturing industry. The global relevant market size exceeded 12 billion US dollars in 2025, with China contributing over 30%. Driven by both policy support and technological breakthroughs, AI applications continue to deepen in biomedicine, industrial enzymes and other fields, opening up vast opportunities for artificial intelligence enterprises.
As a recipient of the title Excellent Enterprise in Artificial Intelligence, Matwings has always taken AI technology as its core development focus, specializing in AI protein design—a key frontier of life sciences:
- It has built a dedicated dataset containing nearly 9 billion protein sequences, integrating sequence information of specially functional proteins from extreme environments, laying a solid foundation for model training.
- Independently developed the general AI protein design large model AIACCLBIO®, enabling protein function prediction and design, and shortening the R&D cycle from 2–5 years to merely 2–6 months.
- Established an innovative paradigm of AI design + minimal experimental verification, lifting the R&D success rate from the traditional 0.1%–1% to 30%, and substantially cutting project costs.
- Advanced the industrial implementation of AI technology, with over 30 industrial projects delivered and partnerships covering leading enterprises at home and abroad, effectively empowering industrial upgrading with tangible AI value.
Going forward, Matwings will continue to delve into the frontier of AI protein design, consolidate its benchmark status as an Excellent Enterprise in Artificial Intelligence through technological innovation, accelerate the industrialization of AI-enabled biomanufacturing, and inject stronger AI momentum into the development of China’s new quality productivity.
